v
Search
Advanced Search

Publications > Journals > Journal of Exploratory Research in Pharmacology > Article Full Text

  • Original Article
  • OPEN ACCESS

Synthesis and Antimicrobial Activity of Naphthylamine Analogs Having Azetidinone and Thiazolidinone Moiety

  • Bhawna Chopra1,2,*,
  • Ashwani K. Dhingra1,
  • Ram P. Kapoor1 and
  • Deo N. Parsad3
 Author information
Journal of Exploratory Research in Pharmacology   2017;2(4):105-112

doi: 10.14218/JERP.2017.00005

Abstract

Background and Objective

To synthesize 2-naphthylamine analogs containing azetidin-2-one (4a–g) and thiazolidin-4-one (5a–g) ring moiety, with the aim of finding new potent antimicrobial agents.

Methods

The antimicrobial activities (antibacterial and antifungal) of the newly-prepared compounds were tested in vitro against bacterial cultures (Bacillus subtilis, Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa) and fungal culture (Candida albicans) using agar plate diffusion antimicrobial bioassay. The structures of the title compounds were supported by their spectral data (IR, 1H NMR and 13C NMR).

Results

The synthetic methodology used for the synthesis of the title compounds is shown in Scheme 1 in the paper. Among all the prepared analogs, four compounds (4a, 4e, 4g and 4f) exhibited broad spectrum activity, as compared to the standard drug (ampicillin). Another three compounds (3b, 5b and 5e) showed remarkable antifungal activity, as compared with the standard drug (amphotericin B).

Conclusions

The present investigation led to the synthesis and biological evaluation of naphthylamine analogs having azetidin-2-one and thiazolidin-4-one heterocyclic nucleus/moiety.

Keywords

Antimicrobial, 2-Azetidinone, 4-Thiazolidinone, Schiff bases, Naphthalene

Introduction

The discovery, development and identification of biologically active antimicrobial compounds have gained a lot of importance in recent years, even though there are a considerable number of adverse effects. Medicinal chemists have always been tried to design drug molecules that possess maximum therapeutic application while having minimum toxicity profile. Moreover, because of excessive use of antibacterial antibiotics, immunosuppressants and cytotoxins, opportunistic mycosis has become prominent. To combat the increasing number of fungal pathogens and the growing burden of resistance, there is a need to develop new antimicrobial compounds.

Naphthalene analogs occupy a central place among medicinally important compounds, due to their diverse and interesting antibiotic properties.1 Napthalene is the simplest and the most important member of the arene class, in which two benzene rings are fused in ortho positions. The effectiveness of this structural feature is demonstrated by β-naphthol having almost the same carbon skeleton; it is commonly used as a dye, and reported to possess very good antimicrobial property.2 Several naphthalene nucleus-containing drugs are also available, such as nafacillin, naftifine, tolnaftate, terbinafine, etc. (Fig. 1), all of which play a vital role in the control of microbial infection.1

Structure of clinically used naphthalene nucleus-containing antimicrobial drugs.
Fig. 1  Structure of clinically used naphthalene nucleus-containing antimicrobial drugs.

On the other hand, the imine and azomethine groups (–N=CH–) have been found, respectively, in various natural, natural-derived and non-natural compounds (Fig. 2) and have been shown to be critical to their biological activities.3–5 They occupy a central place among medicinally important compounds due to their wide spectrum of biological properties, including antimicrobial,6 anti-inflammatory,7 analgesic,8 anti-tubercular,8,9 antimycobacterial,10 antioxidant,11 antiviral,12 inhibitory,13 cytotoxic,14 anticonvulsant,15 anti-proliferative,16 anticancer,17 and antifungal activities.18 Schiff bases of aromatic aldehydes with effective conjugation system are more stable than the aliphatic aldehydes.

Structure of clinically used imine group-containing drugs.
Fig. 2  Structure of clinically used imine group-containing drugs.

Moreover, numerous analogs of azetidinone andthiazolidinone moieties have also been well documented.19–21 Various reports of studies of naphthalene and its based analogs bearing the azetidine and thiazolidone nucleus possess pharmacological potential.22,23 However, the biological activity of this class of compounds deserves further investigation. The purpose of this present study was to evaluate the antimicrobial potential of azetidinone and thiazolidinone analogs of napthylamine.

Material and methods

Chemistry

All the chemicals used were of synthetic grade and commercially procured from Qualigen (Mumbai, India) and CDH (New Delhi, India). Melting points were determined by open capillary tube method and are uncorrected. Fourier-transform infrared spectroscopy (FTIR) spectra (KBr pellet, neat) were recorded on a Perkin Elmer RX1 spectrophotometer and 1H–nuclear magnetic resonance (NMR) and 13C-NMR spectra were recorded on a Brucker 300 MHz spectrometer in (CDCl3) using tetramethylsilane (TMS) as an internal reference and the chemical shifts are expressed in δ ppm. Progress of the reaction and purity of the compound was monitored by thin layer chromatography using a 0.2 mm thick aluminium sheet precoated with silica gel (60F 254; Merck, United States). Spots were visualized under UV (254 nm) and iodine chamber. The solvent was removed under reduced pressure, using a rotary evaporator (Buchi, United States). All other organic solvents used were of laboratory reagent grade, dried over anhydrous sodium sulfate and used as received.

Synthesis of Schiff bases (3a–g)

The appropriate aryl aldehydes (0.01 mol) were added to a solution of β-napthylamine (1.43 g, 0.01 mol) in ethanol (20 mL), followed by dropwise addition of concentrated sulphuric acid. The reaction mixture was then refluxed for 6–8 h and cooled. After cooling, the solid obtained was filtered, washed thoroughly with water, and dried. The pure product was crystallized from ethanol/water (1/1 v/v).

Synthesis of 3-chloro-4-(substituted phenyl)-1-(naphthalen-6-yl)azetidin-2-one (4a–g)

A solution of compound (3a–g, 0.01 mol) in dioxane (20 mL) and triethylamine (0.01 mol) was mixed with continuous stirring. The total mixture was then cooled at 0–5 °C and a few drops of chloroacetyl chloride were added. After addition, the whole mixture was stirred for 5–6 h and then filtered. The filtrate was then refluxed for another 5–6 h and allowed to cool at room temperature. On cooling, a solid crude product separated out, which was filtered, dried and re-crystalized with ethanol.

Synthesis of N-2-(substituted phenyl)-3-(naphthalen-6-yl) thiazolidin-4-one (5a–g)

A mixture of compound (3a–g, 0.01 mol) and thioglycollic acid (0.01 mol) was refluxed on a heating mantle at 120–125 °C for approximately 12 h. The reaction mixture was cooled and treated with 10% sodium bicarbonate solution. The product was isolated and re-crystallized from methanol–dioxane (4:1). The overall reaction scheme followed is depicted in Scheme 1.

Reagents and conditions.
Scheme 1  Reagents and conditions.

a. sulphuric acid, ethanol, 5–6 h reflux.; b. Triethylamine, dioxane, chloroacetyl chloride, stirring followed by 5–6 h reflux, ethanol.; c. Thioglycollic acid, 12h reflux, 10% sodium bicarbonate solution.

4-(naphthalen-3-ylimino methyl) phenol 3a

Molecular formula C17H13NO; melting point 116–117 °C; yield 60%. Infrared (IR) (KBr, cm−1) 3,045.0 (CH), 1,440–1,514 (–H–C=N). 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 8.2 (s, 1H, CH), 4.9 (s, 1H, OH), 6.7–7.4 (m, 11H, Ar–H). 13C-NMR (300 MHz, CDCl3) δ: 160.6, 150.4, 135.2, 132.4, 130, 129.4, 128.2, 126.4, 120.4, 119.2, 116.

3,4,5-trimethoxybenzylidenenaphthalen-2-amine 3b

Molecular formula C20H19NO3; melting point 131–132 °C; yield 60%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3.7 (s, 9H, OCH3), 8.3 (s, 1H, CH), 6.6–7.4 (m, 9H, Ar–H). 13C-NMR (300 MHz, CDCl3) δ: 160.4, 150.6, 141.5, 135, 132.2, 129.4, 128.2, 126.2, 120.6, 119.2, 106.2, 56.2.

3,4-dimethoxybenzylidene naphthalen-2-amine 3c

Molecular formula C19H17NO2; melting point 128–130 °C; yield 60%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3.6 (s, 6H, OCH3), 8.1 (s, 1H, CH), 6.7–7.6 (m, 10H, Ar–H).

2-methoxy-4-(naphthalen-3-ylimino methyl) phenol 3d

Molecular formula C18H15NO2; melting point 114–115 °C; yield 60%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3.7 (s, 3H, OCH3), 5.0 (s, 1H, OH), 8.2 (s, 1H, CH), 6.7–7.4 (m, 10H, Ar–H). 13C-NMR (300 MHz, CDCl3) δ: 160.1, 151.4, 150.2, 148, 135.2, 132.2, 129.4, 128, 127.4, 123, 120.4, 119.2, 117, 114.8, 56.

Benzylidenenaphthalen-2-amine 3e

Molecular formula C17H13N; Melting point 106–107 °C; Yield 60%; 1HNMR (300 MHz, CDCl3, TMS = 0) δ: 8.1 (s, 1H, CH), 7.2–7.6 (m, 12H, Ar–H).

3-nitrobenzylidenenaphthalen-2-amine 3f

Molecular formula C17H12N2O2; melting point 122–123 °C; yield 70%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 8.5 (s, 1H, Ar–H), 8.3 (s, 1H, CH), 8.1–8.2 (d, 2H, Ar–H), 7.3–7.6 (m, 8H, Ar–H).

4-chlorobenzylidenenaphthalen-2-amine 3g

Molecular formula C17H12ClN; melting point 124–125 °C; yield 65%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 8.1 (s, 1H, CH), 7.3–7.6 (m, 11H, Ar–H).

3-chloro-4-(4-hydroxyphenyl)-1-(naphthalen-3-yl)azetidin-2-one 4a

Molecular formula C19H14ClNO2; melting point 146–147 °C; yield 60%; IR (KBr, cm−1) 3,450.5 (NH), 3,047.0 (CH), 1,754.1 (C=O), 1,624.9 (CO–NH), 1,448.7 (CN), 896.5, 750.5 and 677.8(C=C), 679.8 (C–Cl). 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 5.0 (s, 1H, OH), 5.2 (d, 1H, CH), 5.4 (d, 1H, CH), 6.8–7.4 (m, 11H, Ar–H). 13C-NMR (300 MHz, CDCl3) δ: 162.1, 156.4, 141.2, 136.4, 133.2, 128, 127.4, 126.1, 125.4, 124, 121.4, 118.2, 115, 108.6, 63, 62.2.

3-chloro-4-(3,4,5-trimethoxyphenyl)-1-(naphthalen-3-yl)azetidin-2-one 4b

Molecular formula C22H20ClNO4; melting point 134–135 °C; yield 60%; 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3.5 (s, 9H, OCH3), 5.1 (d, 1H, CH), 5.4 (d, 1H, CH), 6.1 (s, 2H, Ar–H), 6.7–7.5 (m, 7H, Ar–H). 13C-NMR (300 MHz, CDCl3) δ: 162.2, 150.3, 141.2, 137.2, 133.2, 127.4, 126.5, 125.3, 124.2, 121.4, 118.1, 108.2, 104, 63, 62.2, 56.

3-chloro-4-(3,4-dimethoxyphenyl)-1-(naphthalen-3-yl)azetidin-2-one 4c

Molecular formula C21H18ClNO3; melting point 128–130 °C; yield 60%.; IR (KBr, cm−1): 3,228.0 (N–H), 3,045.0 (C–H), 1,749.4 (C=O), 1,672.2 (CO–NH), 1,420.0 (C–N), 832.8 and 779.8 (C–C), 689.2 (C–Cl). 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3.6 (s, 6H, OCH3), 5.2 (d, 1H, CH), 5.3 (d, 1H, CH), 6.6–7.6 (m, 10H, Ar–H).

3-chloro-4-(4-hydroxy-3-methoxyphenyl)-1-(naphthalen-3-yl)azetidin-2-one 4d 22

Molecular formula C20H16ClNO3; melting point 134–135 °C; yield 60%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3.7 (s, 3H, OCH3), 4.9 (s, 1H, OH), 5.1 (d, 1H, CH), 5.4 (d, 1H, CH), 6.6–7.4 (m, 10H, Ar–H). 13C–NMR (300 MHz, CDCl3) δ: 162.1, 151.2, 143.2, 141.4, 137.2, 133.2, 127.4, 126.5, 125.3, 124.3, 121.4, 120.6, 118.1, 116, 112.2, 108.2, 63, 62.2, 56.2.

3-chloro-1-(naphthalen-3-yl)-4-phenylazetidin-2-one 4e

Molecular formula C19H14ClNO; melting point 118–119 °C; yield 60%. IR (KBr, cm−1): 3,469.6 (NH), 3,054.0 (CH), 1,756.8 (C=O), 1,670.8 (CO–NH), 1,444.4 (C–N), 854.5, 679.2(C=C), 689.2 (C–Cl). 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 5.1 (d, 1H, CH), 5.4 (d, 1H, CH), 6.8–7.4 (m, 12H, Ar–H).

3-chloro-1-(naphthalen-3-yl)-4-(3-nitrophenyl)azetidin-2-one 4f

Molecular formula C19H13ClN2O3; melting point 122–124 °C; yield 70%. IR (KBr, cm−1): 3,449.5 (NH), 3,045.0 (CH); 1,757.1 (C=O), 1,622.9 (CO–NH), 1,446.7(CN), 894.5, 750.5 and 677.8 (C=C), 677.8 (C–Cl). 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 5.4 (d, 1H, CH), 5.2 (d, 1H, CH), 6.8–7.5 (m, 9H, Ar–H), 8.0–8.1(m, 2H, Ar–H).

3-chloro-4-(4-chlorophenyl)-1-(naphthalen-3-yl)azetidin-2-one 4g

Molecular formula C19H13Cl2NO; melting point 128–129 °C; yield 65%; IR (KBr, cm−1): 3,238.0 (N–H), 3,049.0 (C–H), 1,750.4 (C=O), 1,673.2 (CO–NH), 1,422.0 (C–N), 834.5 and 779.8 (C–C), 619.9 (C–Cl). 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 5.4 (d, 1H, CH), 5.1 (d, 1H, CH), 6.8–7.4 (m, 11H, Ar–H).

4-(4-hydroxyphenyl)-3-(naphthalen-3-yl)thiazolidin-2-one 5a

Molecular formula C19H15NO2S; melting point 126–127 °C; yield 60%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 5.0 (s, 1H, OH), 4.8 (t, 1H, CH), 3.25 (dd, 2H, J = 5.6 Hz, CH2), 6.8–7.4 (m, 11H, Ar–H). 13C–NMR (300 MHz, CDCl3) δ: 170.1, 156.4, 141.2, 136.4, 133.2, 128, 127.4, 126.1, 125.4, 124, 121.4, 118.2, 115, 108.6, 55, 35.2.

4-(3,4,5-trimethoxyphenyl)-3-(naphthalen-3-yl)thiazolidin-2-one 5b

Molecular formula C22H21NO4S; melting point 128–130 °C; yield 65%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3.25(dd, 2H, J = 5.6 Hz, CH2), 3.7 (s, 9H, OCH3), 5.2 (t, 1H, CH), 6.2–7.4 (m, 9H, Ar–H).

4-(3,4-dimethoxyphenyl)-3-(naphthalen-3-yl)thiazolidin-2-one 5c

Molecular formula C21H19NO3S; melting point 133–134 °C; yield 58%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3. 27 (dd, 2H, J = 5.7 Hz, CH2), 3.7 (s, 6H, OCH3), 5.2 (t, 1H, CH), 6.6–7.4 (m, 10H, Ar–H).

4-(4-hydroxy-3-methoxyphenyl)-3-(naphthalen-3-yl)thiazolidin-2-one 5d 22

Molecular formula C20H17NO3S; melting point 137–138 °C; yield 55%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3.32 (dd, 2H, J = 5.6 Hz, CH2), 3.6 (s, 3H, OCH3), 4.9 (s, 1H, OH), 5.1 (t, 1H, CH), 6.6–7.4 (m, 10H, Ar–H).

3-(naphthalen-3-yl)-4-phenylthiazolidin-2-one 5e

Molecular formula C19H15NOS; melting point 134–135 °C; yield 68%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3.34 (dd, 2H, J = 5.8 Hz, CH2), 5.1 (t, 1H, CH), 6.8–7.5 (m, 12H, Ar–H).

3-(naphthalen-3-yl)-4-(3-nitrophenyl)thiazolidin-2-one 5f

Molecular formula C19H14N2O3S; melting point 121–122 °C; yield 60%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3.35 (dd, 2H, J = 5.74 Hz, CH2), 5.2 (t, 1H, CH), 6.8–7.6 (m, 9H, Ar–H), 8.1–8.2 (m, 2H, Ar–H).

4-(4-chlorophenyl)-3-(naphthalen-3-yl)thiazolidin-2-one 5g

Molecular formula C19H14ClNOS; melting point 136–137 °C; yield 70%. 1H–NMR (300 MHz, CDCl3, TMS = 0) δ: 3.36 (dd, 2H, J = 5.75, CH2), 5.0 (t, 1H, CH), 6.8–7.6 (m, 11H, Ar–H).

In vitro antimicrobial activity test

The in vitro antimicrobial potential of all newly prepared analogs was tested at Guru Gobind Singh College of Pharmacy, (Yamuna Nagar, India) using the Agar plate diffusion antimicrobial bioassay. Antimicrobial activity of all the synthesized analogs (3a–g, 4a–g and 5a–g) were tested against four standard bacterial cultures (i.e. Bacillus subtilis MTCC 121, Staphylococcus aureus MTCC 96, Escherichia coli MTCC 739 and Pseudomonas aeruginosa MTCC 2453) and one fungal strain (Candida albicans MTCC 3017) according to the literature as described.24 The stock solutions for all new prepared compounds (3a–g, 4a–g and 5a–g; 5,000 µg/mL each) were prepared in DMSO (50 µg per well, i.e. 250 µg) and the activity was determined by measuring the zone of inhibition. The strength (i.e. 50 µg/mL) was used as positive control for the bioassay. The antibacterial and antifungal potentials of the prepared analogs were compared with the standard drugs ampicillin (200 µg/mL) and amphotericin B (500 µg/mL), respectively. Activity was determined by measuring the diameter of zones showing complete inhibition (mm). Growth inhibition was calculated with reference to the positive control.

Results and discussion

Chemistry

All of the new azetidinone and thiazolidione analogs of napthylamine were synthesized successfully, with the subsequent aim of finding new compounds with promising antibacterial activities. The synthetic methodology is shown in Scheme 1. The purity and structures of all the synthesized compounds were elucidated on the basis of their spectral data (i.e. IR, 1H–NMR and 13C–NMR). The IR spectra of 3a–g compounds displayed the characteristic peaks in the region of 1,440–1,514 cm−1 indicating the formation of a Schiff base (–H–C=N). The appearance of peaks in the region of 1,550–1,687 cm−1 confirmed the presence of C=O in 4a–g and 5a–g. The structural assignments were further supported by their 1H–NMR spectra, and all the synthesized compounds were found to be in conformity with the structures envisaged. The molecular properties of the title compounds, such as log P, topological polar surface area (TPSA), number of atoms other than hydrogen (Natom), number of hydrogen bond donor (nON) and number of H– bond acceptor (n OHNH), were calculated by the online Molinspiration software and the data recorded are given in Table 1.25

Table 1

Molecular properties of the 3a–g, 4a–g and 5a–g compounds

CompoundArLogPTPSANatomnONnOHNH
3a–4OHC6H44.1732.591921
3b–3,4,5–triOCH3C6H24.2940.072440
3c–3,4–diOCH3C6H34.3030.832230
3d–4OH,3–OCH3C6H33.9941.832131
3e–C6H54.6512.361810
3f–3NO2C6H44.5958.192140
3g–4ClC6H45.3312.361910
4a–4OHC6H44.1040.542331
4b–3,4,5–triOCH3C6H24.2148.012850
4c–3,4–diOCH3C6H34.2338.782640
4d–4OH,3–OCH3C6H33.9249.772541
4e–C6H54.5820.312220
4f–3NO2C6H44.5166.132550
4g–4ClC6H45.2620.312320
5a–4OHC6H44.5840.542331
5b–3,4,5–triOCH3C6H24.6948.012850
5c–3,4–diOCH3C6H34.7038.782640
5d–4OH,3–OCH3C6H34.4049.772541
5e–C6H55.0620.312220
5f–3NO2C6H44.9966.132550
5g–4ClC6H45.7420.312320

Antibacterial activity

The antibacterial potential of prepared analogs was compared with the standard drug ampicillin, whereas the antifungal potential was compared with the standard drug amphotericin B (Table 2). The observation was made over 2 days and the “–” sign signifies no zone of inhibition (ZOI). In many cases, on the first day, ZOI was observed but had disappeared on the next day.

Table 2

Antibacterial and antifungal potential of all the synthesized analogs

CompoundB. subtilis MTCC 121
S. aureus MTCC 96
E. coli MTCC 739
P. aeruginosa MTCC 2453
C. albicans MTCC 3017
24h48h24h48h24h48h24h48h24h48h
3a10mm–––––––––
3b––––––––7mm–
3c––––––––––
3d––––––––––
3e12mm–––––––––
3f––––––––––
3g––––––––––
4a9mm9mm12mm10mm––10mm10mm––
4b––––––––––
4c––––––––––
4d12mm–15mm–––––––
4e10mm10mm––19mm–9mm–––
4f16mm15mm15mm15mm––19mm–13mm–
4g12mm15mm––––14mm–––
5a––12mm–––––––
5b––––––––9mm–
5c––––––––––
5d––––20mm20mm––––
5e13mm–––––––13mm–
5f––––––––––
5g13mm–––11mm–––––
Positive control27mm22mm44mm45mm15mm17mm––16mm15mm
(ampicillin 200µg/mL)(ampicillin 200µg/mL)(ampicillin 200µg/mL)(amphotericin B, 500µg/mL)
DMSO (control)––––––––––

Schiff base analogs in this series (3a–g) showed no activity against any of the bacteria tested. Three compounds, 4a, 4e and 4g, were found to exhibit broad spectrum activity. Compound 4d showed good activity against B. subtilis MTCC 121 (12 mm) and moderate activity against S.aureus MTCC 96 (15 mm). However, compound 4f showed a wide spectrum of antimicrobial activity, but it may be cytotoxic. Compounds 3b, 5b and 5e were found to be active against C. albicans MTCC 3017, with ZOIs at 24 h 7 mm, 9 mm and 13mm, respectively. Although ampicillin is a broad spectrum antibiotic, it is inactive against Pseudomonas species at the tested concentration, which may be due to some mutation.

Future research directions

N-heterocyclic nucleus and its analogues have attracted the interest of many medicinal chemists, and because of this many modifications have been carried out in last decade. Keeping this in view, the work in this study was carried out with different approaches to develop better analogs of napthylamine analogs having azetidin-2-one and thiazolidin-4-one moiety with comparable antimicrobial activity. The promising activity of these compounds, along with the other activity data obtained during the study, can also be useful in establishing the structure activity relationships and for the development of newer and more potent antimicrobial compounds which will able to act against multidrug resistance.

Conclusions

In summary, the present investigation describes the synthesis and biological evaluation of naphthylamine analogs having azetidin-2-one and thiazolidin-4-one heterocyclic nucleus/moiety. All the prepared analogs were characterized by suitable methods, such as IR and 1H–NMR. All spectral data were in accordance with assumed structures. The three compounds 4a, 4e, 4g and 4f exhibited broad spectrum activity.

Abbreviations

FTIR: 

Fourier-transform infrared spectroscopy

IR: 

infrared

Natom: 

number of atoms other than hydrogen

NMR: 

nuclear magnetic resonance

nOHNH: 

number of H– bond acceptor

nON: 

number of hydrogen bond donor

TMS: 

tetramethylasilane

TPSA: 

topological polar surface area

ZOI: 

zone of inhibition

Declarations

Acknowledgement

The authors extend their heartfelt gratitude to IK Gujral Punjab Technical University, Kapurthala, Punjab, India and Dr. Jagdeep Singh Dua, Shivalik College of Pharmacy, Nangal, Punjab, India for valuable suggestions and moral support.

Conflict of interest

The authors have no conflict of interests related to this publication.

Authors’ contributions

Overall experimental work (BC), preparation of manuscript (BC), Analysis (AK), revision of analysis (RPK), research guidance (DNP).

References

  1. Rokade YB, Sayyed RZ. Naphthalene derivatives: a new range of antimicrobials with high therapeutic value. RasayanJ Chem 2009;2:972-980
  2. Delgado JN. Wilson and Gisvold’s textbook of organic medicinal and pharmaceutical chemistry. Lippincott: Williams and Wilkins, Philadelphia; 2004, 255-257
  3. Dhar DN, Taploo CL. Schiff bases and their applications. J SciInd Res 1982;1:501-506
  4. Bringmann G, Dreyer M, Faber JH, Dalsgaard PW, Staerk D, Jaroszewski JW. Ancistrotanzanine C and related 5,1′- and 7,3′-coupled naphthylisoquinoline alkaloids from Ancistrocladus tanzaniensis. J Nat Prod 2004;67:743-748 View Article
  5. de Souza AO, Galett FCS, Silva CL, Bicalho B, Parma MM, Fonseca SF. Antimycobacterial and cytotoxicity activity of synthetic and natural compounds. Quim Nova 2007;30:1563-1566 View Article
  6. da Silva CM, da Silva DL, Modolo LV, Alves RB, de Resende MA, Martins CVB. Schiff bases: A short review of their antimicrobial activities. J Adv Res 2011;2:1-8 View Article
  7. Lin SJ, Tsai WJ, Chiou WF, Yanga TH, Yanga LM. Selective COX-2 inhibitors. Part 2: Synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem 2008;16:2697-2706 View Article
  8. Gemma S, Savini L, Altarelli M, Tripaldi P, Chiasserini L, Coccone SS. Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure–activity relationship studies. Bioorg Med Chem 2009;17:6063-6072 View Article
  9. Hearn MJ, Cynamon MH, Chen MF, Coppins R, Davis J, Kang HJ. Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid. Eur J Med Chem 2009;44:4169-4178 View Article
  10. Raparti V, Chitre T, Bothara K, Kumar V, Dangre S, Khachane C. Novel 4-(morpholin-4-yl)-N′-(arylidene)benzohydrazides: Synthesis, antimycobacterial activity and QSAR investigations. Eur J Med Chem 2009;44:3954-3960 View Article
  11. Cheng LX, Tang JJ, Luo H, Jin XL, Dai F, Yang J. Antioxidant and antiproliferative activities of hydroxyl-substituted Schiff bases. Bioorg Med Chem Lett 2010;20:2417-2420 View Article
  12. Jarrahpour A, Khalili D, Clercq ED, Salmi C, Brunel JM. Synthesis, Antibacterial, Antifungal and Antiviral Activity Evaluation of Some New bis-Schiff Bases of Isatin and Their Derivatives. Molecule 2007;12:1720-1730 View Article
  13. Khan KM, Ambreen N, Hussain S, Perveen S, Choudhary MI. Schiff bases of 3-formylchromone as thymidine phosphorylase inhibitors. Bioorg Med Chem 2009;17:2983-2988 View Article
  14. Tarafder MT, Kasbollah A, Saravanan N, Crouse KA, Ali AM, Tin Oo K. S-methyldithiocarbazate and its Schiff bases: evaluation of bondings and biological properties. Biochem Mol Biol Biophys 2002;6:85-91 View Article
  15. Kucukguzel I, Kucukguzel SG, Rollas S, Sanis GO, Ozdemir O, Bayrak I. Synthesis of some 3-(Arylalkylthio)-4-alkyl/aryl-5-(4-aminophenyl)-4H-1,2,4-triazole derivatives and their anticonvulsant activity. Farmaco 2004;59:893-901 View Article
  16. Vicini P, Geronikaki A, Incerti M, Busonera B, Poni G, Kabras CA. Synthesis and Biological Evaluation of Benzo[d]isothiazole, Benzothiazole and Thiazole Schiff Bases. Bioorg Med Chem 2003;11:4785-4789 View Article
  17. Bekircan O, Kahveci B, Kucuk M. Synthesis and anticancer evaluation of some new unsymmetrical 3, 5-diaryl-4H-1, 2, 4-triazole derivatives. Tur J Chem 2006;30:29-40
  18. Guo Z, Xing R, Liu S, Zhong Z, Ji X, Wang L. Antifungal properties of Schiff bases of chitosan, N -substituted chitosan and quaternized chitosan. Carbohydr Res 2007;342:1329-1332 View Article
  19. Jain AK, Vaidya A, Ravichandran V, Kashaw SK, Agrawal RK. Recent developments and biological activities of thiazolidinone derivatives: a review. Bioorg Med Chem 2012;20:3378-95 View Article
  20. Zachariah SM, Ramkumar M, George N, Ashif MS. Azetidinones: An overview. Int J Pharm Sci Rev Res 2015;30:211-218
  21. De Rosa M, Vigliotta G, Palma G, Saturnino C, Soriente A. Novel penicillin-type analogues bearing a variable substituted 2-Azetidinone ring at position 6: synthesis and biological evaluation. Molecules 2015;20:22044-22057 View Article
  22. Sharma S, Singh T, Mittal R, Saxena KK, Srivastava VK, Kumar A. A study of anti-inflammatory activity of some novel α-Amino naphthalene and β-Amino naphthalene derivatives. Arch Pharm (Weinheim) 2006;339:145-152 View Article
  23. Baig MZK, Pallikonda G, Trivedi P, Tulichala RNP, Ghosh B, Chakravarty M. Metal-free arylation to access distinct anthracenylphosphonates and anticancer activities for these and allied phosphonates. Chem 2016;1:4332-4339 View Article
  24. Atta-ur-Rahman MI, Choudhary WJT. Bioassay Techniques for Drug Development. The Netherlands: Harwood Academic Publishers; 2001, 15-22
  25. http://www.molinspiration.com
Copyright © 2017 Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • Journal of Exploratory Research in Pharmacology
  • pISSN 2993-5121
  • eISSN 2572-5505

Article Options

Metrics

Cite this Article

  • © 2024 Xia & He Publishing Inc.
  • Total visits : 1972762
  • Visits today : 3204
Back to Top

Synthesis and Antimicrobial Activity of Naphthylamine Analogs Having Azetidinone and Thiazolidinone Moiety

Bhawna Chopra, Ashwani K. Dhingra, Ram P. Kapoor, Deo N. Parsad
  • Reset Zoom
  • Download TIFF